Calgary Scientific’s ResolutionMD received FDA clearance for diagnosis on mobile devices for most imaging modalities.
ResolutionMD, an enterprise image-viewing solution, has been approved by the U.S. Food and Drug Administration (FDA) for diagnosis on mobile devices for most imaging modalities.
Calgary Scientific, Inc., the company behind ResolutionMD, worked with multiple radiologists worldwide to clinically validate the solution before submitting it to the FDA. ResolutionMD allows doctors to securely view patient images and reports from a variety of computers and mobile devices. It also offers the ability to collaborate with other practitioners and diagnose from any location.
The mobile medical diagnosis software of ResolutionMD can be integrated into any EMR and plugged into existing distributed storage systems. The FDA’s safety and effectiveness review found ResolutionMD to be substantially equivalent to PACS or dedicated diagnostic workstations.
ResolutionMD has been cleared to diagnose modalities such as CR, DR, radio-fluoroscopy, angiography, ultrasound, nuclear medicine, endoscopy and ophthalmology.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.